Cargando…

Ulcerative colitis associated with nephrotic syndrome after treatment with mesalazine developed into rectal carcinoma: a case study

BACKGROUND: Previous studies reported that nephrotic syndrome is associated with ulcerative colitis (UC) patients treated with mesalazine. Dysplasia associated with UC often develops into colorectal carcinoma. CASE PRESENTATION: A 17-year-old man was referred to our hospital, complaining of diarrhea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sameshima, Shinichi, Koketsu, Shinichiro, Okuyama, Takashi, Kubota, Yawara, Ono, Yuko, Noie, Tamaki, Oya, Masatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957919/ https://www.ncbi.nlm.nih.gov/pubmed/27450459 http://dx.doi.org/10.1186/s12957-016-0950-1

Ejemplares similares

Surgical resections of ulcerative colitis associated with dysplasia or carcinoma
por: Sameshima, Shinichi, et al.
Publicado: (2015)

Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer: a single-center, retrospective cohort study
por: Okuyama, Takashi, et al.
Publicado: (2018)

Comparison of postoperative plasma D‐dimer levels between patients undergoing laparoscopic resection and conventional open resection for colorectal cancer
por: Kubota, Yawara, et al.
Publicado: (2020)

Myxoid stroma is associated with postoperative relapse in patients with stage II colon cancer
por: Okuyama, Takashi, et al.
Publicado: (2020)

Obstruction in the third portion of the duodenum due to a diospyrobezoar: a case report
por: Yamagata, Yukinori, et al.
Publicado: (2017)

Rectal carcinoma and multiple gastrointestinal stromal tumors (GIST) of the small intestine in a patient with neurofibromatosis type 1: a case report
por: Hakozaki, Yuhei, et al.
Publicado: (2017)

A case with mesenteric desmoid tumor after laparoscopic resection of stage I sigmoid colon cancer
por: Takada, Musashi, et al.
Publicado: (2019)

Mesalazine-induced myopericarditis in a patient with ulcerative colitis
por: Asadi, Jalal, et al.
Publicado: (2017)

Recurrent Mesalazine-Induced Myopericarditis in a Patient with Ulcerative Colitis
por: Park, Eun Hye, et al.
Publicado: (2012)

Mesalazine-Induced Interstitial Nephritis in a Patient With Ulcerative Colitis
por: da Cunha Marques, José, et al.
Publicado: (2022)

Efficacy of oral prolonged‐release mesalazine in moderately active ulcerative colitis
por: Paridaens, Kristine, et al.
Publicado: (2023)

Crohn's Disease with Mesalazine Allergy that Was Difficult to Differentiate from Comorbid Ulcerative Colitis
por: Tsuboi, Rumiko, et al.
Publicado: (2018)

The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
por: Yuichiro, Ohtaki, et al.
Publicado: (2022)

Integrated Analysis Reveals the Targets and Mechanisms in Immunosuppressive Effect of Mesalazine on Ulcerative Colitis
por: Li, Rong, et al.
Publicado: (2022)

Mesalazine granules promote disease clearance in patients with mild‐to‐moderate ulcerative colitis
por: Kruis, Wolfgang, et al.
Publicado: (2023)

Efficacy of Combined Mesalazine Plus Corticosteroid Enemas for Diversion Colitis after Subtotal Colectomy for Ulcerative Colitis
por: Matsumoto, Satohiro, et al.
Publicado: (2016)

Efficacy of Long-Term 4.0 g/Day Mesalazine (Pentasa) for Maintenance Therapy in Ulcerative Colitis
por: Takeshima, Fuminao, et al.
Publicado: (2014)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Acute Pancreatitis due to pH-Dependent Mesalazine That Occurred in the Course of Ulcerative Colitis
por: Arai, Yoshinori, et al.
Publicado: (2011)

Mesalazine-related lung disease in a patient with ulcerative colitis: A case report
por: Huang, Po-Han, et al.
Publicado: (2018)

Systematic Evaluation of Randomized Clinical Trials of Huangqin Tang in Combination with Mesalazine for Ulcerative Colitis
por: Pan, Chengyu, et al.
Publicado: (2022)

Correction: The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
por: Ohtaki, Yuichiro, et al.
Publicado: (2023)

Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study
por: Ogata, Haruhiko, et al.
Publicado: (2017)

Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine
por: Prenzler, Anne, et al.
Publicado: (2011)

Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis
por: Böhm, Stephan Karl, et al.
Publicado: (2014)

Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report
por: Khanna, Raoul Kanav, et al.
Publicado: (2018)

Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial
por: Rubin, David T., et al.
Publicado: (2016)

Efficacy and safety of low-dose thalidomide combined with mesalazine in the treatment of refractory ulcerative colitis in adults
por: Chen, Jun-Rong, et al.
Publicado: (2022)

Combined Diosmectite and Mesalazine Treatment for Mild-to-Moderate Ulcerative Colitis: A Randomized, Placebo-Controlled Study
por: Jiang, Xue-Liang, et al.
Publicado: (2015)

Is once daily multimatrix mesalazine therapy effective regardless of the dose in patients with mild to moderate ulcerative colitis?
por: Jeon, Seong Ran
Publicado: (2018)

Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
por: Yagisawa, Keiji, et al.
Publicado: (2019)

Comparative Transcriptomic Analysis Reveals the Immunosuppressive Targets of Mesalazine in Dextran Sulfate Sodium-Induced Ulcerative Colitis
por: Li, Rong, et al.
Publicado: (2021)

Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
por: Ogata, Haruhiko, et al.
Publicado: (2017)

Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
por: Yagisawa, Keiji, et al.
Publicado: (2020)

A Rare Case of Mesalazine-Induced Acute Myocarditis in a 19-Year-Old Female With Ulcerative Colitis
por: Ali, Abuobeida, et al.
Publicado: (2021)

A Case Report and Literature Review of Mesalazine-Induced Kidney Injury in a Pediatric Patient With Ulcerative Colitis
por: Wang, Shuo, et al.
Publicado: (2022)

Ulcerative Colitis Activity Presenting as Fever of Unknown Origin, in a Patient with Longstanding Disease under Continuous Treatment with Mesalazine
por: Voukelatou, Panagiota, et al.
Publicado: (2016)

Gancao Xiexin decoction combined with mesalazine in the treatment of ulcerative colitis: A protocol for a systematic review and meta-analysis
por: Zhong, Chun, et al.
Publicado: (2020)

Mesalazine suppository for the treatment of refractory ulcerative chronic radiation proctitis
por: Wu, Changliang, et al.
Publicado: (2018)

Increased Gene Copy Number of DEFA1A3 Is Associated With the Severity of Ulcerative Colitis
por: Kanmura, Shuji, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dgiu32ldjuvp7ivnkpnf764f9d